Literature DB >> 7786395

Synthesis and biological evaluation of amino-substituted benzo[f]pyrido[4,3-b] and pyrido[3,4-b]quinoxalines: a new class of antineoplastic agents.

C H Nguyen1, E Fan, J F Riou, M C Bissery, P Vrignaud, F Lavelle, E Bisagni.   

Abstract

In order to study the structure-activity relationships in the series of new intercalating polycyclic agents, 1-amino-substituted pyrido[3,4-b]quinoxalines, benzo[f]pyrido[4,3-b]quinoxaline derivatives bearing a dibasic side chain and their benzo[f]pyrido[3,4-b] isomers have been synthesized. Biological evaluation was carried out for topoisomerase I and II inhibition, and for in vitro and in vivo antitumor properties in several models. Results demonstrate that appropriately substituted benzo[f]pyrido[4,3-b]quinoxaline derivatives are inhibitors of topoisomerase I and II, and have significant antitumor properties in various experimental models. In addition, the most active compounds appear to be minimally recognized by tumor cells expressing the multidrug resistance phenotype.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7786395

Source DB:  PubMed          Journal:  Anticancer Drug Des        ISSN: 0266-9536


  3 in total

1.  Rational design of a triple helix-specific intercalating ligand.

Authors:  C Escudé; C H Nguyen; S Kukreti; Y Janin; J S Sun; E Bisagni; T Garestier; C Hélène
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-31       Impact factor: 11.205

2.  Ligand binding mode to duplex and triplex DNA assessed by combining electrospray tandem mass spectrometry and molecular modeling.

Authors:  Frédéric Rosu; Chi-Hung Nguyen; Edwin De Pauw; Valérie Gabelica
Journal:  J Am Soc Mass Spectrom       Date:  2007-03-28       Impact factor: 3.109

Review 3.  Recent advances in the transition-metal-free synthesis of quinoxalines.

Authors:  Biplob Borah; L Raju Chowhan
Journal:  RSC Adv       Date:  2021-11-19       Impact factor: 4.036

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.